The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
Open accessAbstract
The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence‐based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in October 2021 in Japanese. In addition to surveillance–diagnostic and treatment algorithms, a new algorithm for systemic therapy has been created, as multiple drugs for hepatocellular carcinoma can be currently selected. Here, new or revised algorithms and evidence on which the recommendations are based are described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationMazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Self-citationBruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Self-citationLlovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Kokudo, N., Takemura, N., Hasegawa, K., Takayama, T., Kubo, S., Shimada, M., Nagano, H., Hatano, E., Izumi, N., Kaneko, S., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13411 · Cited by 521
Self-citationKokudo, T., Hasegawa, K., Matsuyama, Y., Takayama, T., Izumi, N., Kadoya, M., Kudo, M., Ku, Y., Sakamoto, M., Nakashima, O., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.044 · Cited by 491
Self-citationKokudo, N., Hasegawa, K., Akahane, M., Igaki, H., Izumi, N., Ichida, T., Uemoto, S., Kaneko, S., Kawasaki, S., Ku, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12464 · Cited by 391
Self-citationNg, K. K. C., Chok, K. S. H., Chan, A. C. Y., Cheung, T. T., Wong, T. C. L., Fung, J. Y. Y., Yuen, J., Poon, R. T. P., Fan, S. T., & Lo, C. M. (2017) · British Journal of Surgery · doi:10.1002/bjs.10677 · Cited by 331
Makuuchi, M., Kokudo, N., Arii, S., Futagawa, S., Kaneko, S., Kawasaki, S., Matsuyama, Y., Okazaki, M., Okita, K., Omata, M., et al. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00216.x · Cited by 294
Self-citationTakayama, T., Hasegawa, K., Izumi, N., Kudo, M., Shimada, M., Yamanaka, N., Inomata, M., Kaneko, S., Nakayama, H., Kawaguchi, Y., et al. (2022) · Liver Cancer · doi:10.1159/000521665 · Cited by 207
Self-citationKokudo, T., Hasegawa, K., Matsuyama, Y., Takayama, T., Izumi, N., Kadoya, M., Kudo, M., Kubo, S., Sakamoto, M., Nakashima, O., et al. (2017) · Hepatology · doi:10.1002/hep.29225 · Cited by 195
Self-citationShimamura, T., Akamatsu, N., Fujiyoshi, M., Kawaguchi, A., Morita, S., Kawasaki, S., Üemoto, S., Kokudo, N., Hasegawa, K., Ohdan, H., et al. (2018) · Transplant International · doi:10.1111/tri.13391 · Cited by 163
Self-citationMakuuchi, M. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i5.828 · Cited by 111
Kudo, M., Hasegawa, K., Kawaguchi, Y., Takayama, T., Izumi, N., Yamanaka, N., Shimada, M., Inomata, M., Kaneko, S., Baba, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4093 · Cited by 32
Self-citation
Cited by
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
Metadata
- Authors
- Hasegawa, K., Takemura, N., Yamashita, T., Watadani, T., Kaibori, M., Kubo, S., Shimada, M., Nagano, H., Hatano, E., Aikata, H., Iijima, H., Ueshima, K., Ohkawa, K., Genda, T., Tsuchiya, K., Torimura, T., Ikeda, M., Furuse, J., Akahane, M., Kobayashi, S., Sakurai, H., Takeda, A., Murakami, T., Motosugi, U., Matsuyama, Y., Kudo, M., Tateishi, R., & The committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, T.
- Venue
- Hepatology Research
- Publisher
- Wiley
- Published
- 2023-03-10
- Volume
- 53
- Issue
- 5
- Pages
- 383-390
- ISSN
- 1386-6346 (ISSN-L)
- 1872-034X
- OpenAlex
- W4321748197
- Cited by
- 296
- References
- 18
- FWCI
- 41.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.